Cancer vaccine firm Oxford Vacmedix appoints Eurofins CDMO as Contract Development & Manufacturing Organisation

Oxford Vacmedix appoints Belgium based Eurofins CDMO to carry out the GMP manufacturing of the lead immunotherapy cancer vaccine OVM-200, to support Phase 1 application.

Oxford, UK – 22nd November 2019

Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today that Eurofins CDMO based in Belgium has been appointed to complete the GMP (Good Manufacturing Practice) manufacture of its lead immunotherapy cancer vaccine, OVM- 200.

Eurofins CDMO will focus on the GMP manufacturing of OVM-200 based on the process development work to produce GMP material already successfully completed. In parallel the GLP (Good Laboratory Practice) material already produced by Xpress Biologics will be used for preclinical formulation and toxicity development and for the choice of the optimal adjuvant for Phase 1 clinical trials, to start next year. Previous work on manufacturing was carried out in China and independently by the Structural Genomics Centre (SGC) in Oxford and was then transferred to Xpress Biologics to support the GMP manufacturing development of OVM’s two lead vaccines, OVM-100 and OVM-200. OVM-100 is an HPV vaccine targeted at cervical cancer, and OVM-200 represents a new type of vaccine utilising survivin to target solid tumours. Both vaccines are being tested as single agents and in combination with other immune-oncology (IO) agents.

Spun out from the University of Oxford, OVM is commercialising the research led by Dr Shisong Jiang and developed in Oxford University’s Department of Oncology. The technology uses the novel, proprietary platform of recombinant overlapping peptides to design and develop therapeutic cancer vaccines and diagnostics with the potential for increased efficacy, lower costs, simpler regulatory pathways and synergy when used in combination with other IO agents.

William Finch, CEO and Director at OVM, said:

“We are very pleased to have such an experienced company as Eurofins CDMO involved in the manufacturing development of OVM-200 and with the teamwork that has allowed us to reach this point. This next phase of work on OVM-200 will enable the start of Phase 1 next year. We look forward to OVM’s lead cancer vaccine being progressed to this important clinical milestone, both to benefit patients and to enhance significant shareholder value”

Yves Gonnissen, Business Line Director of the European Eurofins CDMO business, added:

“We are delighted to have been appointed to complete the next phase of the manufacturing work on Oxford Vacmedix’s lead immunotherapy cancer vaccine and look forward to a productive and beneficial partnership with the company. We are confident that we can support the continued growth and development of the company.”

For more information or to arrange an interview, please contact:
William Finch, CEO, Oxford Vacmedix
T: +44 (0)1865 742074 | M: +44(0)7769 903711 | E:

About Oxford Vacmedix

Oxford Vacmedix UK Ltd, based on the Oxford Science Park, UK, is a bio-pharma company that utilizes the novel proprietary platform technology of recombinant overlapping peptides (ROPs) invented by Dr Shisong Jiang. ROPs have been validated as a technology to stimulate broad and strong T cell immunity therefore forming a good platform for cancer therapeutic vaccines and diagnostics. The company is a spin-out of the University of Oxford and has extensive contacts and collaborations in China through Changzhou Bioscience (CBI) that is using the ROP platform in both diagnostics and adoptive cell therapy..

For more information, please visit:

About Eurofins CDMO, Belgium

Eurofins CDMO is one of the leading CDMO’s providing high-quality, customized drug development solutions for specialty and biopharma clients. The focus is to support clients on the earliest phases of their development pathway (from drug substance to clinical packaging). The company’s innovative and flexible approach enables customers to speed up their drug development process, achieving key milestones in a timely manner.

For more information, please visit: